S.F.-Based McKesson Corp. Subpoenaed in Opioid Probe

Save ArticleSave Article

Failed to save article

Please try again

This article is more than 4 years old.
The McKesson corporate headquarters is seen June 4, 2003, in San Francisco. (Justin Sullivan/Getty Images)

New York state prosecutors have served the McKesson Corp. with a subpoena in connection with a multistate investigation into the San Francisco-based drug distribution giant's opioid marketing and sales practices.

The office of New York Attorney General Eric Schneiderman confirmed Thursday that it served McKesson, the nation's largest prescription drug distributor, and Ohio-based Cardinal Health, with subpoenas, seeking company records and communications related to suspicious drug orders.

"We've received the attorney general's subpoena and are currently reviewing its specific requests," said McKesson spokeswoman Kristin Hunter Chasen in an email.

Schneiderman's office is working with prosecutors in several other states.

"These AGs are jumping on an already fast-moving bandwagon," said Michelle Mello, a professor of law, health research and policy at Stanford University.


The subpoenas are the latest in a series of state and federal efforts to scrutinize and penalize McKesson, which is believed to distribute one-third of all pharmaceuticals used in North America, for its links to the nation's opioid crisis.

The House Energy and Commerce Committee is investigating shipments McKesson and other companies made to pharmacies in small towns in West Virginia.

Last year, McKesson agreed to a settlement with the U.S. Justice Department and paid a $150 million fine in civil penalties for alleged violations of the Controlled Substances Act.

In 2008, McKesson agreed to a $13 million civil penalty for similar violations.

Federal prosecutors say that, between 2008 and 2013, McKesson supplied pharmacies an increasing amount of oxycodone and hydrocodone pills.

Prosecutors in several states, cities and counties have sued the company as well as other large drug distributors and manufacturers.

Mello says that litigation could lead to a "global settlement."

"This is going to be a very difficult path for the company to tread, and that really bodes well for the states attorney general," Mello said.

In early March, lawyers representing West Virginia in its lawsuit over that state's opioid epidemic revealed that they planned to depose several top McKesson executives in the coming months. Five of the company's officials are slated to be interviewed starting the week of April 12.

In that lawsuit, the company is accused of offering bonuses to employees for increased opioid sales. McKesson disputes that claim.

Late last month, McKesson filed papers in Oklahoma state court to get a lawsuit filed by the Cherokee Nation moved into federal court.

The tribe says the San Francisco company and several other firms, including Walgreens, Walmart and CVS Health, caused and perpetuated the opioid abuse epidemic in the Cherokee Nation.

Last September, California Attorney General Xavier Becerra announced that California and 40 other states were expanding their investigation into the opioid crisis, which included more scrutiny of McKesson.

His office noted that opioids are the main driver of drug overdose deaths in the country. The drugs were involved in more than 33,000 deaths nationwide in 2015.

That year, approximately 2,000 Californians died due to overdoses related to opioid use.